It also gives Parkinson's researchers their best model system yet for investigating how and why the disease strikes.
Comparison to our findings is confounded by the presence of nuclease-inhibiting surfactant, distinct nanostructure designs, and an alternative in vivo model system, yet the observed differences suggest that DNA-based nanomaterials may be sensitive to their environment in a design-dependent manner.
This poses challenges for understanding and modeling such systems, yet modeling is often the only option to study them.
In this study we have acquired preliminary evidence that the use of mucomodulators yields acceptable mucociliary clearance in an ex vivo epithelial model, increases "expectoration" in a model system, and yet achieves a desired target of a significant reduction in fine aerosol formation.
These findings also help to reconcile the disparate findings that immune therapeutic approaches can be used successfully in preclinical model systems but have yet to achieve successful responses in the vast majority of patients by demonstrating the importance of the tumor hypoxic environment in markedly inducing the immune suppressive properties of the GBM.
In contrast, yeast model systems have not yet advanced our understanding of mammalian cell death mechanisms.
So much seems to have been done — using different model systems and nanomaterials — and yet, there are grumbles throughout the literature about the slow progress2, misconceptions in and of the field3, and proposals on what the community needs to do as a whole for the field to progress faster4.
This strategy, known as spermatogonial stem cell transplantation, has been successful in mice and other model systems, but has not yet been applied in humans.
This coupling requires the development of new computational approaches and the systematic pairing of these new approaches with cutting-edge experimental studies in model systems that are informative yet tractable.
Despite the enormous effort that has already been made to understand the biochemical and cellular mechanisms that lead to the development of immune tolerance in model systems, we do not yet understand how to re-institute immune self tolerance in individuals that have already developed autoimmune disease.
